Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
First Claim
Patent Images
1. A method for determining metabolism of a test agent in a tissue comprising:
- A) incubating a test agent and an enzyme within a three-dimensional tissue engineered system, such that an enzyme-substrate complex is formed between the enzyme and the test agent; and
B) detecting one or more metabolites of the test agent.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention generally relates to a combination of the fields of tissue engineering, drug discovery and drug development. It more specifically provides new methods and materials for testing the efficacy and safety of experimental drugs, defining the metabolic pathways of experimental drugs and characterizing the properties (e.g., side effects, new uses) of existing drugs. Preferably, evaluation is carried out in three-dimensional tissue-engineered systems, wherein drug toxicity, metabolism, interaction and/or efficacy can be determined.
-
Citations
26 Claims
-
1. A method for determining metabolism of a test agent in a tissue comprising:
-
A) incubating a test agent and an enzyme within a three-dimensional tissue engineered system, such that an enzyme-substrate complex is formed between the enzyme and the test agent; and
B) detecting one or more metabolites of the test agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. A method of determining toxicity of a test agent in a tissue comprising:
-
A) incubating a test agent within a three-dimensional tissue engineered system; and
B) detecting an undesired effect. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
-
23. A method for determining efficacy of a test agent, wherein efficacy comprises activity sufficient to decrease or eliminate hepatitis C virus in liver tissue comprising:
-
A) incubating a test agent within a three-dimensional liver tissue engineered system; and
B) measuring levels of hepatitis C virus.
-
-
24. A method for determining efficacy of a test agent, wherein efficacy comprises activity sufficient to decrease or eliminate hepatitis C virus in liver tissue comprising:
-
A) incubating a test agent within a three-dimensional liver tissue engineered system; and
B) detecting improved liver function. - View Dependent Claims (25, 26)
-
Specification